OPENING OF BANKRUPTCY

EGEIRO PHARMA

Export PDF

Financial year 2023 · closed on 31/12/2023

Net result

-1,6 M €

+32.2% YoY

Revenue

117,8 k €

+25.3% YoY

Equity

6 M €

-19.6% YoY

Workforce

7,5 ETP

-37.0% YoY

Company — Opening of bankruptcy.

What does EGEIRO PHARMA do?

EGEIRO PHARMA is a Public limited company incorporated in 2017. Its main activity is: Manufacture of other inorganic basic chemicals. Its registered office is in Charleroi. It employs on average 7,5 ETP workers (FTE).

Legal situation

● Opening of bankruptcy

BCE/KBO no. / VAT

BE 0684.906.013

Incorporation

22/11/2017

Legal form

Public limited company

Registered office

Avenue Jean Mermoz 32 box 1
6041 Charleroi · WallonieSee on map

Contributed capital

10 172 458,50 €

Latest accounts

31/12/2023

Average workforce

7,5 ETP

Activities (NACE)

20130Manufacture of other inorganic basic chemicals· main 20130Manufacture of other inorganic basic chemicals

Joint committees (2)

Signals

Solid equityGood liquidityHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 6 financial years

	2023		2022		2021		2020		2019		2018
Income statement
Revenue	117,8 k €	+25.3%	94 k €	+662%	12,3 k €		–		–		–
EBITDA	-1,1 M €	+33.9%	-1,7 M €	-43.7%	-1,2 M €	-230%	-354,8 k €	-299%	-88,8 k €	+9.9%	-98,6 k €
Operating result	-2,2 M €	+21.7%	-2,8 M €	-60.6%	-1,7 M €	-331%	-401,2 k €	-321%	-95,3 k €	+24.0%	-125,5 k €
Net result	-1,6 M €	+32.2%	-2,3 M €	-72.7%	-1,3 M €	-245%	-388,5 k €	-293%	-98,9 k €	+23.0%	-128,4 k €
Balance sheet
Equity	6 M €	-19.6%	7,5 M €	-22.0%	9,6 M €	+184%	3,4 M €	+119%	1,5 M €	+15.5%	1,3 M €
Total assets	7,5 M €	-20.7%	9,5 M €	-17.0%	11,5 M €	+124%	5,1 M €	+145%	2,1 M €	+26.4%	1,7 M €
Cash	1,1 M €	-64.0%	3,2 M €	-43.4%	5,6 M €	+160%	2,2 M €	+2562%	81,4 k €	-91.7%	983,1 k €
Debts	1,5 M €	-25.1%	2 M €	+10.0%	1,8 M €	+4.9%	1,7 M €	+218%	537,3 k €	+73.1%	310,3 k €
Other
Workforce	7,5 ETP	-37.0%	11,9 ETP	+54.5%	7,7 ETP	+57.1%	4,9 ETP		–		–

Governance

Board of directors

Seen on filing of 31/12/2023 · 5 active · 14 ended

Active mandates

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 04 juin 2026 · 0723.875.762

Represented by Nesya GORIS

Active

Simon WHEELER

Director · since 14 décembre 2021 · until 04 juin 2026

Active

ENRICO BASTIANELLI sprl

Director · since 21 décembre 2017 · until 06 juin 2024 · 0883.830.544

Represented by BASTIANELLI ENRICO

Active

ORSA ADMIN

Director · since 21 décembre 2017 · until 23 août 2023 · 0890.073.384

Represented by MATHIEU JEAN-PHILIPPE

Active

Julie WINAND

Director · since 22 novembre 2017 · until 11 août 2023

Active

Ended mandates

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 04 juin 2026 · 0723.875.762

Represented by Nesya GORIS

Ended

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 01 juin 2023 · 0723.875.762

Represented by Nesya GORIS

Ended

Simon WHEELER

Director · since 14 décembre 2021 · until 01 juin 2023

Ended

50°NORTH VENTURES

Director · since 03 mai 2021 · until 14 décembre 2021 · 0507.740.263

Represented by Mohamed Lotfi YELLES CHAOUCHE

Ended

At this address

Other companies at this address

Company	CBE no.
IPRATECH● Active	0893.778.586
Minoryx Therapeutics BE● Active	0713.984.534

Annual accounts

Full financial information

	2023	2022	2021	2020	2019	2018
Type of account	Full model	Full model	Full model	Full model	Micro model	Micro model
Start of the financial year	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019	21/11/2017
Closing of the financial year	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019	31/12/2018
Length of the financial year	12 months	12 months	12 months	12 months	12 months	14 months
Filing date	08/08/2024	06/06/2023	28/06/2022	21/06/2021	17/07/2020	28/06/2019
General meeting	06/06/2024	01/06/2023	02/06/2022	03/05/2021	17/06/2020	21/06/2019
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

6 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2023	06/06/2024	08/08/2024	French	PDF
Full model	31/12/2022	01/06/2023	06/06/2023	French	PDF
Full model	31/12/2021	02/06/2022	28/06/2022	French	PDF
Full model	31/12/2020	03/05/2021	21/06/2021	French	PDF
Micro model	31/12/2019	17/06/2020	17/07/2020	French	PDF
Micro model	31/12/2018	21/06/2019	28/06/2019	French	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2023 · 5 active · 14 ended

Active mandates

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 04 juin 2026 · 0723.875.762

Represented by Nesya GORIS

Active

Simon WHEELER

Director · since 14 décembre 2021 · until 04 juin 2026

Active

ENRICO BASTIANELLI sprl

Director · since 21 décembre 2017 · until 06 juin 2024 · 0883.830.544

Represented by BASTIANELLI ENRICO

Active

ORSA ADMIN

Director · since 21 décembre 2017 · until 23 août 2023 · 0890.073.384

Represented by MATHIEU JEAN-PHILIPPE

Active

Julie WINAND

Director · since 22 novembre 2017 · until 11 août 2023

Active

Ended mandates

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 04 juin 2026 · 0723.875.762

Represented by Nesya GORIS

Ended

Nesya Goris LifeSciences Consulting

Director · since 14 décembre 2021 · until 01 juin 2023 · 0723.875.762

Represented by Nesya GORIS

Ended

Simon WHEELER

Director · since 14 décembre 2021 · until 01 juin 2023

Ended

50°NORTH VENTURES

Director · since 03 mai 2021 · until 14 décembre 2021 · 0507.740.263

Represented by Mohamed Lotfi YELLES CHAOUCHE

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Other20/12/2024
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Capital / shares17/12/2024
CAPITAL, ACTIONS
PDF
Mandates13/12/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates22/11/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates12/11/2024
DENOMINATION - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Capital / shares18/09/2024
CAPITAL, ACTIONS
PDF
Capital / shares06/09/2024
CAPITAL, ACTIONS
PDF
Mandates18/07/2024
DEMISSIONS, NOMINATIONS
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2023
Annual accounts 2023-1,6 M €↑
2022
Annual accounts 2022-2,3 M €↓
2021
Annual accounts 2021-1,3 M €↓
2020
Annual accounts 2020-388,5 k €↓
2019
Annual accounts 2019-98,9 k €↑
2018
Annual accounts 2018-128,4 k €
22/11/2017
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

EGEIRO PHARMA

Overview

What does EGEIRO PHARMA do?

Trend over 6 financial years

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline